BMJ 2003;327 (30 August), doi:10.1136/bmj.327.7413.0
Bisphosphonates reduce skeletal morbidity in cancer patients
In patients with metastatic bone disease bisphosphonates reduce skeletal morbidity and increase the time to first skeletal related event. In a systematic review of 30 randomised controlled trials, Ross and colleagues (p 469) found that bisphosphonates significantly decrease the risk of vertebral fractures, non-vertebral fractures, radiotherapy, and hypercalcaemia but not orthopaedic surgery or spinal cord compression. They also delay the time to first skeletal related event, suggesting that bisphosphonates should be started when bone metastases are diagnosed.
|
CiteULike 
Complore 
Connotea 
Del.icio.us 
Digg 
Reddit 
StumbleUpon 
Technorati What's this?
Relevant Article
- Systematic review of role of bisphosphonates on skeletal morbidity in metastatic cancer
- J R Ross, Y Saunders, P M Edmonds, S Patel, K E Broadley, and S R D Johnston
BMJ 2003 327: 469.[Abstract] [Full Text] [PDF]
This Article
- Respond to this article
- Alert me when this article is cited
- Alert me when responses are posted
- Alert me when a correction is posted
Services
- Email this article to a friend
- Find similar articles in BMJ
- Add article to my folders
- Download to citation manager
- Request Permissions
Citing Articles
Google Scholar
Related Content
Bookmark with
What's new
Latest blogs
Find BMJ on:
Services
Tools
Online poll
Resources
Rapid responses for this article
There are no rapid responses for this article. Print issues
